Fractional treatment of rosacea by LBO 532 nm laser with “one shot” procedure: A preliminary study

Published: 27 December 2022
Abstract Views: 1471
PDF: 113
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Rosacea is a chronic skin disease prevalently affecting the center of the face. The permanent erythema of skin face represents its typical sign. Further common features are face flushing, telangiectasias, and inflammatory presence of oedema, papules and pustules. The aim of this study was to investigate the use of LBO 532nm laser in the treatment of this disease. Ten subjects of both sex and middle age affected by rosacea in erithemato/teleangectatic stage were treated by a LBO 532nm laser single session. Discomfort evaluation during and after the treatment, one session results as well as incidence of the side effects were evaluated, with 6 months follow up. Positive results were obtained after only one session in total safety with minimal patients discomfort and without undesired effects during treatment. The study confirmed International literature data suggesting the use of laser and light devices as elective treatment of this disease. IPL, dye lasers and 532nm laser are the devices more used and the last seems to represent the gold standard for 1,2,3 phototypes. This clinical trial, with the limitations due to the small number of patients, indicated that “one session LBO 532nm laser treatment” represents an interesting and innovative approach in the therapy of the erythemato/telangectatic rosacea.



PlumX Metrics


Download data is not yet available.


van Zuuren EJ. Rosacea. N Engl J Med 2017;377:1754–64. DOI:
Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea Consensus 2019 panel. Br J Dermatol 2020;182:1269–76. DOI:
Zhang H, Tang K, Wang Y, et al. Rosacea treatment: review and update. Dermatol Ther (Heidelb) 2021;11:13–24 DOI:
Abokwidir M, Feldman SR. Rosacea management. Skin Appendage Disord 2016;2:26–34. DOI:
Meki´c S, Hamer M, Wigmann C, et al. Epidemiology and determinants of facial telangiectasia: A cross-sectional study. J Eur Acad Dermatol Venereol 2020;34:821–6. DOI:
Baldwin HE, Harper J, Baradaran S, Patel V. Erythema of rosacea affects health-related quality of life: results of a survey conducted in collaboration with the National Rosacea Society. Dermatol Ther (Heidelb) 2019;9:725–34. DOI:
Holmes AD, Spoendlin J, Chien AL, et al. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol 2018;78:156–66. DOI:
Cribier B. Rosacea: Treatment targets based on new physiopathology data. Ann Dermatol Venereol 2022;149:99-107. DOI:
Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013;69:S15–26. DOI:
Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Investig Dermatol 2015;135:1548–55. DOI:
van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 2019;181:65-79. DOI:
Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017;176:465–471. DOI:
Kim M, Kim J, Jeong SW, et al. Long-pulsed 1064-nm Nd: YAG laser ameliorates LL-37-induced rosacea-like skin lesions through promoting collagen remodeling in BALB/c mice. Lasers Med Sci 2018;33:393-7. DOI:
Jasim ZF, Woo WK, Handley JM. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg 2004;30:37-40. DOI:
Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg 2003;29:600-4. DOI:
Liu J, Liu J, Ren Y, et al. Comparative efficacy of intense pulsed light for different erythema associated with rosacea. J Cosmet Laser Ther 2014;16:324-7. DOI:
Bassichis BA, Swamy R, Dayan SH. Use of the KTP laser in the treatment of rosacea and solar lentigines. Facial Plast Surg 2004;20:77-83. DOI:
Fornaini C, Rocca JP, Merigo E, et al. Low energy KTP laser in oral soft tissue surgery: A 52 patients clinical study. Med Oral Patol Oral Cir Bucal 2012;17:e287-91. DOI:
Taylor JG, Disario JA, Bjorkman DJ. KTP laser therapy for bleeding from chronic radiation proctopathy. Gastrointest Endosc 2000;52:353–7. DOI:
Nammour S, Kowaly K, Powell GL, et al. External temperature during KTP-Nd:YAG laser irradiation in root canals: an in vitro study. Lasers Med Sci 2004;19:27–32. DOI:
Gamache FW Jr, Patterson RH Jr. The use of the potassium titanyl phosphate (KTP) laser in neurosurgery. Neurosurgery 1990;26:1010–3 DOI:
Tugcu V, Tasci AI, Sahin S, et al. Outcomes of 80 W KTP laser vaporization of the large prostate. Urol Int 2007;79:316–320. DOI:
Heinrich E, Schiefelbein F, Schoen G. Technique and short-term outcome of green light laser (KTP, 80W) vaporisation of the prostate. Eur Urol 2007;52:1632–7. DOI:
Burns JA, Zeitels SM, Akst LM, et al. 532 nm pulsed potassium-titanyl-phosphate laser treatment of laryngeal papillomatosis under general anesthesia. Laryngoscope 2007;117:1500–04. DOI:
McGee TM, Diaz-Ordaz EA, Kartush JM. The role of KTP laser in revision stapedectomy. Otolaryngol Head Neck Surg 1993;109:839–43. DOI:
Nagayasu T, Matsumoto K, Morino S, et al. Limited lung resection using the potassium-titanyl-phosphate laser. Lasers Surg Med 2006;38:290–5. DOI:
West TB, Alster TS. Comparison of the long-pulse dye (590-595 nm) and KTP (532 nm) lasers in the treatment of facial and leg telangiectasias. Dermatol Surg 1998;24:221–6. DOI:
Zorn KC, Liberman D. GreenLight 180W XPS photovaporization of the prostate: how I do it. Can J Urol 2011;18:5918-26.
Kang HW, Jebens D, Malek RS, et al. Laser vaporization of bovine prostate: a quantitative comparison of potassium-titanyl-phosphate and lithium triborate lasers. J Urol 2008;180:2675-80. DOI:
Reich O. Greenlight: from potassium-titanyl-phosphate to lithium triborate or from good to better? Curr Opin Urol 2011;21:27-30. DOI:
Marangoni O, Longo L. Lasers in Phlebology, IALMS publisher, 2006.
Mansouri Y, Goldenberg G. Devices and topical agents for rosacea management. Cutis 2014;94:21–5.
Micali G, Gerber PA, Lacarrubba F, Schäfer G. Improving treatment of erythematotelangiectatic rosacea with laser and/or topical therapy through enhanced discrimination of its clinical features. J Clin Aesthet Dermatol 2016;9:30-9.
Becher GL, Cameron H, Moseley H. Treatment of superficial vascular lesions with the KTP 532-nm laser: experience with 647 patients. Lasers Med Sci 2014;29:267-71. DOI:
Railan D, Parlette EC, Uebelhoer NS, Rohrer TE. Laser treatment of vascular lesions. Clin Dermatol 2006;24:8–15. DOI:
Piccolo D, Zalaudek I, Genovesi C, et al. Long-pulsed Nd:YAG laser using an "in motion" setting to treat telangiectatic rosacea. Ann Dermatol Venereol 2022;S0151-9638(22)00093-X. DOI:

How to Cite

Lazzari, R., Fornaini, C., & Longo, L. (2022). Fractional treatment of rosacea by LBO 532 nm laser with “one shot” procedure: A preliminary study. Laser Therapy, 29(2).